Eliem appoints Aoife Brennan as CEO and director, effective upon Tenet merger close

Climb Bio, Inc.

Aoife Brennan appointed President and CEO, base salary $650K/yr, annual bonus target 55%.
Equity grant: incentive option for 550K shares and 275K RSUs, vesting over 4 years.
Stephen Thomas (Tenet CEO) appointed to board, expected to serve as consultant post-merger.
Andrew Levin to step down as principal executive officer but remain principal financial officer.
All appointments effective upon closing of Tenet acquisition; meeting on June 26, 2024.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Aoife Brennan

President and Chief Executive Officer

CLYM · Climb Bio, Inc.

Filed: June 12, 2024, 7:59 PM ET

appointed Aoife Brennan as President and Chief Executive Officer of Eliem, subject to and contingent and effective upon the closing of the Acquisition

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aoife Brennan was appointed as President and Chief Executive Officer at Climb Bio, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointed Aoife Brennan as President and Chief Executive Officer of Eliem, subject to and contingent and effective upon the closing of the Acquisition

View on SEC.gov

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-159994

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.